Kaposi's Sarcoma: Evaluation of Clinical Features, Treatment Outcomes, and Prognosis in a Single-Center Retrospective Case Series
Irene Russo,Dario Marino,Claudia Cozzolino,Paolo Del Fiore,Fitnete Nerjaku,Silvia Finotto,Annamaria Cattelan,Maria Luisa Calabrò,Anna Belloni Fortina,Francesco Russano,Marcodomenico Mazza,Sara Galuppo,Elisabetta Bezzon,Marta Sbaraglia,Marco Krengli,Antonella Brunello,Simone Mocellin,Stefano Piaserico,Mauro Alaibac
DOI: https://doi.org/10.3390/cancers16040691
2024-02-07
Cancers
Abstract:Kaposi's sarcoma (KS) is a rare angioproliferative tumor classified in four different clinical–epidemiological forms. The diagnosis is based on histopathological and immunohistochemical analyses. The treatment is heterogeneous and includes several local and systemic therapeutic strategies. Methods: This is a retrospective cohort study including 86 KS patients treated between 1993 and 2022 at the University Hospital of Padua (AOPD) and at the Veneto Institute of Oncology (IOV). The data were extracted from an electronic database. Survival curves were generated using the Kaplan–Meier method, and Cox regression models were employed to explore associations with overall and disease-free survival. The male sex (89.53%), classical variant (43.02%), and cutaneous involvement (77.9%) were predominant. More than 61.6% of patients received a single treatment. Surgery, antiretroviral therapy, and chemotherapy were the mostly adopted approaches. A persistent response was observed in approximately 65% of patients, with a 22% relapse rate (at least 2 years). The overall survival ranges from 90 to 70% at 2 to 10 years after the diagnosis. Iatrogenic KS demonstrated a higher mortality (52.9%). This study reflects our experience in the management of KS. Comorbidities are very frequent, and treatments are heterogeneous. A multidisciplinary approach involving multiple referral specialists is essential for the appropriate management of this disease during diagnosis, treatment, and follow-up.
oncology